These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31436251)

  • 41. MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
    Lung J; Hung MS; Lin YC; Lee KF; Jiang YY; Huang SL; Fang YH; Lu MS; Lin CK; Yang TM; Lin PY; Hsieh MJ; Tsai YH
    PLoS One; 2019; 14(8):e0220670. PubMed ID: 31369639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
    Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Wong SK; Alex D; Bosdet I; Hughesman C; Karsan A; Yip S; Ho C
    Lung Cancer; 2021 Apr; 154():142-145. PubMed ID: 33667719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplification.
    Fu R; Xiong Y; Cai M; Li F; Chen R; Wu Y; Zhong W
    Front Med; 2024 Aug; 18(4):735-743. PubMed ID: 38805102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
    Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
    J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
    Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL
    JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
    Song Z; Wang X; Zheng Y; Su H; Zhang Y
    Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of
    Subramanian J; Tawfik O
    Expert Rev Anticancer Ther; 2021 Aug; 21(8):877-886. PubMed ID: 33957836
    [No Abstract]   [Full Text] [Related]  

  • 49. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
    Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
    Future Oncol; 2024; 20(22):1553-1563. PubMed ID: 38629593
    [No Abstract]   [Full Text] [Related]  

  • 50. Savolitinib as a novel treatment regimen for pulmonary sarcomatoid carcinoma with MET exon 14 skipping mutation.
    Wang Y; Bu Y; Che G
    Asian J Surg; 2024 Jul; 47(7):3308-3309. PubMed ID: 38599970
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
    Bubendorf L; Dafni U; Schöbel M; Finn SP; Tischler V; Sejda A; Marchetti A; Thunnissen E; Verbeken EK; Warth A; Sansano I; Cheney R; Speel EJM; Nonaka D; Monkhorst K; Hager H; Martorell M; Savic S; Kerr KM; Tan Q; Tsourti Z; Geiger TR; Kammler R; Schulze K; Das-Gupta A; Shames D; Peters S; Stahel RA;
    Lung Cancer; 2017 Sep; 111():143-149. PubMed ID: 28838386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
    Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
    Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
    Teishikata T; Shiraishi K; Shinno Y; Kobayashi Y; Kashima J; Ishiyama T; Yoshida T; Mori T; Yatabe Y
    J Thorac Oncol; 2021 Dec; 16(12):2133-2138. PubMed ID: 34419686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
    Qiu T; Li W; Zhang T; Xing P; Huang W; Wang B; Chu L; Guo L; Liu X; Li Y; Ying J; Li J
    Clin Lung Cancer; 2018 Jul; 19(4):e391-e398. PubMed ID: 29338938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
    Watari N; Yamaguchi K; Terada H; Hamai K; Masuda K; Nishimura Y; Sakamoto S; Masuda T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Shoda H; Ishikawa N; Fujitaka K; Miyazaki K; Miyata Y; Hamada H; Awai K; Hattori N
    BMC Pulm Med; 2022 Jun; 22(1):260. PubMed ID: 35773658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
    Yin L; Lu Y
    Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MET alterations in advanced pulmonary sarcomatoid carcinoma.
    Gong C; Xiong H; Qin K; Wang J; Cheng Y; Zhao J; Zhang J
    Front Oncol; 2022; 12():1017026. PubMed ID: 36212500
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.